D03 Category · further specificity required Melanoma in situ
ICD-10-CM D03 identifies “Melanoma in situ” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Chapter 2: Neoplasms
Code-level instructions
No additional notes.
Inherited instructions
Chapters 2 · Neoplasms (C00-D49)
Note8
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
D00-D09 · In situ neoplasms (D00-D09)
Includes4
- Bowen's disease
- erythroplasia
- grade III intraepithelial neoplasia
- Queyrat's erythroplasia
More specific codes
D03.0Melanoma in situ of lipBillable / specificD03.1Melanoma in situ of eyelid, including canthusCategory · further specificity requiredD03.2Melanoma in situ of ear and external auricular canalCategory · further specificity requiredD03.3Melanoma in situ of other and unspecified parts of faceCategory · further specificity requiredD03.4Melanoma in situ of scalp and neckBillable / specificD03.5Melanoma in situ of trunkCategory · further specificity requiredD03.6Melanoma in situ of upper limb, including shoulderCategory · further specificity requiredD03.7Melanoma in situ of lower limb, including hipCategory · further specificity requiredD03.8Melanoma in situ of other sitesBillable / specificD03.9Melanoma in situ, unspecifiedBillable / specificOfficial index references
References from other codes (7)
Excludes 1 · melanoma in situ (D03.-)
Excludes 1 · melanoma in situ (D03.-)
Excludes 1 · melanoma in situ (D03.-)
Excludes 1 · melanoma in situ (D03.-)
Excludes 1 · melanoma in situ (D03.-)
Excludes 1 · melanoma in situ (D03.-)
Inclusion terms · Conditions classifiable to D03
History
Code history
No recorded change since first observation
ChangedUnchanged
FY2016
Effective from
- First observed
Melanoma in situ
Category — select a more specific code
CDC/NCHS · FY2016All editions (19)
| All editions | Effective from | Code history |
|---|---|---|
| FY2016 | 2015-10-01 | First observed |
| FY2017 | 2016-10-01 | No tabular change |
| FY2018 | 2017-10-01 | No tabular change |
| FY2019 | 2018-10-01 | No tabular change |
| FY2020 | 2019-10-01 | No tabular change |
| FY2020 · April | 2020-04-01 | No tabular change |
| FY2021 | 2020-10-01 | No tabular change |
| FY2021 · 01-01 | 2021-01-01 | No tabular change |
| FY2022 | 2021-10-01 | No tabular change |
| FY2022 · 04-01 | 2022-04-01 | No tabular change |
| FY2023 | 2022-10-01 | No tabular change |
| FY2023 · 04-01 | 2023-04-01 | No tabular change |
| FY2024 | 2023-10-01 | No tabular change |
| FY2024 · 04-01 | 2024-04-01 | No tabular change |
| FY2025 | 2024-10-01 | No tabular change |
| FY2025 · 04-01 | 2025-04-01 | No tabular change |
| FY2026 | 2025-10-01 | No tabular change |
| FY2026 · April | 2026-04-01 | No tabular change |
| FY2027 | 2026-10-01 | No tabular change |
Explore the more specific codes in this category. Reference checks do not establish clinical appropriateness or guarantee reimbursement.